| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | shikonin | GDSC1000 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.081 | 0.02 |